Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma

Phase 2 Completed 11 enrolled GlaxoSmithKline

RandomizedCrossoverDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of GSK256066 in the treatment of subjects with mild bronchial asthma, using a number of clinical and biological markers of efficacy.

Timeline

Start: 2006-09
Primary completion: —
Completion: 2007-06

Outcome

Met primary endpoint

paper GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) PMID 20193079 ↗

Publications

Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res. 2010 Mar 1;11(1):26. doi: 10.1186/1465-9921-11-26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GSK256066	Small molecule	87.5 ug	Inhaled